Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib vs dasatinib maintenance after allogeneic HSCT in adult Ph+ acute lymphoblastic leukemia
ChiCTR2100046563Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Flumatinib and dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Recurrence-free survival, Residual disease (minimal residual disease) and 2 more. Started Jun 2021; status: recruiting.
02
Drugs
Flumatinibdasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2100046563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046563.